Magnolia Bark Extract for Anxiety

Verdict: Weak, indirect evidence; magnolia alone unproven for anxiety

Magnolia bark extract is not proven to relieve anxiety. The only human trials tested a magnolia-plus-phellodendron combination (Relora), were small and industry-funded, and showed at most modest, inconsistent effects on stress and mood—so any benefit cannot be attributed to magnolia bark itself.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This claim earns a weak (Tier C) grade because direct human evidence for magnolia bark in anxiety is essentially absent. The only two randomized trials (PMID 23924268, n=56, 4 weeks; PMID 18426577, n=26, 6 weeks) tested the proprietary Relora blend of magnolia and Phellodendron (Amur cork tree), so neither can isolate magnolia's own effect. Both were small, short, industry-funded, and did not report effect sizes.

The signal that exists is thin and mixed. Talbott 2013 (PMID 23924268) reported modest improvements on some POMS mood subscales such as tension and fatigue versus placebo, but in moderately stressed (not clinically anxious) adults. Kalman 2008 (PMID 18426577) was a weight-management pilot in stress-eating women where anxiety was only a secondary, non-significant outcome. The popularized honokiol/magnolol anxiolytic mechanism rests mainly on animal and in vitro work, not human trials.

Authorities do not endorse it. The FDA has treated marketed magnolia/honokiol products as unapproved drugs in an enforcement warning letter, while EFSA, the NHS, WHO, NIH ODS, Mayo Clinic, Cleveland Clinic, Harvard Health, and psychiatric societies do not address it for anxiety at all. With benefit unconfirmed and a noted additive-sedation risk alongside alcohol or CNS depressants, the evidence supports caution rather than recommendation.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.42
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
83%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.425
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Effect of Magnolia officinalis and Phellodendron amurense (Relora) on cortisol and psychological mood state in moderately stressed subjects
PMID: 23924268 2013 RCT (double-blind) n = 56
Finding: Relora group showed significantly higher salivary cortisol AUC and improved overall stress/mood vs placebo on several POMS subscales (e.g. tension, fatigue), p<0.05; effects modest.
⚠️ Industry-funded
View on PubMed
Effect of a proprietary Magnolia and Phellodendron extract (Relora) on weight management: a pilot, double-blind, placebo-controlled clinical trial
PMID: 18426577 2008 RCT (double-blind) n = 26
Finding: Pilot in overweight, stress-eating women; no significant weight change; trend toward reduced transient anxiety/stress in Relora arm but underpowered and not the primary endpoint (NS).
🟠 Limited quality ⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
The claims on your website establish that these products are drugs under section 201(g)(1) of the FD&C Act ... because they are intended for use in the cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body. source↗
L4d TW TFDA / 衛福部
Not addressed
厚朴收載於《臺灣中藥典》,屬中藥材;未列入衛福部中醫藥司公告之「可同時提供食品使用之中藥材」清單。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-magnolia-bark-001 繁體中文版 →